Thursday, October 19, 2017 6:41:15 PM
Typically there is a buy on anticipation, being weeks away, I'm thinking that kicks in soon. So your theory holds water imo.
What's clear to me, along with the small volume, is the lack of real selling pressure. Everything is still getting soaked up. I think the bulls will be taking over soon. No guarantee .63 holds of course but the day to day on the LII's is showing a sense of desperation to accumulate. The chart reflects the accumulation. Buy on fear, sell on glory is VERY much alive here. The weakness is being absorbed. The stochastics is also reflecting a potential rally possibly to your target in the .80's.
I think I'll be very pleased with my buys in the .60's. This isn't a game for the weak. But with the continuous success all along with trials, I'm sleeping pretty good at night. The design of this set of trials takes right from the last set, though pointedly for big pharma for further proof.
I don't think it gets much better than that. They can wait a few more days though so I can pick up another chunk, though I'm considering buying on the way up through the $ instead. My cost basis is very reasonable now getting closer to 1.20. But I'm also not going to lose my house if everything backfires. Which I doubt very much.
$IPIX is a strong buy imo.
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM